COLUMBIA, Md.–(BUSINESS WIRE)–Welldoc®, a digital health leader revolutionizing chronic care, today announced data demonstrating that the use of a digital health application in a virtual program for individuals with type 2 diabetes was associated with significant improvements in weight loss, as well as favorable trends in post-meal blood glucose and systolic blood pressure. The data, which were presented as a clinical research poster at the 18th Annual Cardiometabolic Health Congress in Boston, capture the results of a real-world study in which individuals were given access to the Welldoc App, which provides continuous AI-driven digital coaching designed to support self-management behaviors.
Data show that the average weight at the endpoint was significantly lower than the baseline (227.8 to 211.8 pounds, p=0.007), with over 77% of participants losing an average of 4.8% of their baseline body weight. There were also statistically significant improvements in systolic blood pressure and favorable post-meal blood glucose trends. These data demonstrate how overall cardiovascular risk can be reduced in a high-risk population at scale, validating Welldoc’s approach to developing next-generation digital health solutions.
“With half of the rapidly expanding type 2 diabetes population having or being at-risk for cardiovascular disease,1 as well as a worsening global shortage of healthcare professionals,2 it’s critical to offer a holistic solution which guides individuals through all aspects of their chronic conditions and comorbidities. Digital health offers the opportunity to scale care, lessen the burden on individuals living with these conditions, improve efficiencies for clinicians, and reduce unsustainable medical costs,” said Dr. Mansur Shomali, Chief Medical Officer of Welldoc. “With this research we can clearly see the value of digital health tools which incorporate personalized AI-driven coaching. The ability to improve multiple cardiometabolic outcomes in a high-risk population demonstrates the potential of our solution to amplify the benefits of provider visits for individuals with multiple conditions.”
Welldoc’s comprehensive platform provides digital coaching across multiple chronic conditions and comorbidities, including type 1 and type 2 diabetes, heart failure, prediabetes, hypertension, and weight management, with integrated mental well-being tools.
The company’s AI-driven, total health approach to chronic care continues to lead the industry, as demonstrated by Welldoc’s 78 clinical publications, 42 patents, 11 FDA 510(k) Clearances for type 1 and type 2 diabetes and several awards to date for innovation, AI, and integration into real-world healthcare models.
1National Diabetes Statistics Report website. https://www.cdc.gov/diabetes/data/statistics-report/index.html. Accessed October 11, 2023.
2Dall T, West T, Chakrabarti R, et al: The Complexities of Physician Supply and Demand: Projections from 2016 to 2030, American Association of Medical Colleges, Washington DC, 2018.
About Welldoc
Welldoc®, a digital health leader revolutionizing chronic care, is integrating personalized, real-time and actionable insights into the daily lives of individuals living with chronic conditions, enabling improved health and outcomes. Welldoc’s comprehensive chronic care platform provides multi-condition support across pre-diabetes, diabetes, hypertension, heart failure, weight and obesity management, and mental wellbeing. Welldoc’s flagship product, BlueStar®, an FDA-cleared digital health solution, guides individuals through the complicated journey of living with diabetes by enabling them to self-manage their care while enhancing connections to their healthcare team. Welldoc partners with health plans, health systems and employers with the goal of extending care, improving health and reducing costs. Welldoc continues to be recognized for our leadership, innovation and partnership across the healthcare industry. This year, Welldoc was named the “Best Overall Digital Health Company” by MedTech Breakthrough and received the Innovation and AI Excellence Awards from Business Intelligence Group. In addition to achieving 11 510(k) clearances for its digital health platform designed to support diabetes health, Welldoc has also built an IP portfolio of 42 patents for its advanced AI and first-in-class tech and currently has more than 75 clinical publications. Among Welldoc’s extensive library of clinical research, Welldoc has 17 publications focused on understanding the value of combining CGM with AI-powered digital health solutions. For more information, visit www.welldoc.com. Follow us on LinkedIn and Twitter.
Contacts
MacDougall Advisors
Megan Prock McGrath
781-235-3060
